Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient
NCT06993740
Anesthesia, Cardiovascular Diseases
Jakarta, DKI Jakarta, Indonesia
View Trial DetailsNCT Number: NCT01820949
This study will evaluate clinical outcome after the step-wise implementation of a Patient Blood Management (PBM) Program in surgical patients at 4 hospitals.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
University Hospital Bonn, Bonn, Germany
A PBM program will be implemented stepwise in four University Hospitals, with the intention to optimize preoperative hemoglobin concentration of patients and to standardize transfusion practice within hemotherapy. The PBM program includes 1) an algorithm with the aim to correct preoperative anemia in elective surgery, 2) a strict indication for the transfusion of red blood cells defined by the "Cross-sectional Guidelines for Therapy with Blood Components and Plasma Derivatives" for all surgical patients, and 3) a perioperative checklist for different blood-sparing techniques (e.g. cell-saver, normothermia, reduced blood samples, point-of-care diagnostics for bedside coagulation management).
Primary endpoint: Safety of the use of PBM program will be determined by comparability of the composite outcome (in-hospital myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsis until discharge from hospital) between patients treated after implementation and patients treated before implementation (control cohort) of the PBM program.
The primary composite endpoint defined as described above will be registered electronically by analysis of Diagnosis Related Groups (DRG) codes. The frequency of these events will be compared between PBM and control cohort stratified by center with a one-sided Mantel-Haenszel test in a non-inferiority setting with significance level of α=2.5% and a non-inferiority margin of 1% for the incidence of the composite endpoint.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Composite endpoint defined as in-hospital myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsis until discharge from hospital
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Johann Wolfgang Goethe University Hospital
Other
Acronym: PBM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06993740
Anesthesia, Cardiovascular Diseases
Jakarta, DKI Jakarta, Indonesia
View Trial DetailsNCT05320718
Anesthesia, Local, Regional Anesthesia
Beijing, Beijing Municipality, China
View Trial DetailsNCT05552092
Surgery
Gwangju, South Korea
View Trial DetailsNCT03369210
Anemia, Hematologic Diseases
Aachen, Germany
View Trial Details